Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7?

The development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) changed dramatically the history of non-small cell lung cancer (NSCLC) harboring EGFR sensitive mutations. Several randomized prospective trials confirmed the superiority of these target agents about surviva...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Thorac Dis
Autores principales: Passaro, Antonio, Pochesci, Alessia, Spitaleri, Gianluca, Catania, Chiara, Noberasco, Cristina, Del Signore, Ester, de Marinis, Filippo
Formato: Artigo
Lenguaje:Inglês
Publicado: AME Publishing Company 2016
Materias:
Research Highlight
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4805786/
https://ncbi.nlm.nih.gov/pubmed/27076973
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2016.02.21
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares